New Phase 2a CMT trial results are in. NMD Pharma shares details.
CMT2A in the Lab: A Closer Look at How Treatments Are Tested
What if you could watch CMT2A unfold inside a neuron? CMTA’s new partnership just made it possible, and the early findings are changing the game.
CMT Community Helps Achieve a Major Research Milestone with NMD Pharma
What happens when the CMT community takes action and participates in CMT research? NMD Pharma answers the question.
How the CMT2C Community Is Driving the Path to Treatment
How is the CMT2C community helping move research forward? A CMTA-hosted focus group on how patient voices are shaping the path to a treatment.
This Genetic Tape Could Silence the Cause of CMT2E
What happened when CMTA-supported scientists at the University of Miami applied a piece of genetic tape to the gene mutation that causes CMT2E?
CMTA-STAR Alliance Partner Doses First CMT2S Patient
CMTA-STAR Alliance Partner Doses First CMT2S Patient
CMTA-STAR Partner Applied Therapeutics Presents 24-Month CMT-SORD Data at PNS 2025
The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Applied Therapeutics...
Long Read Sequencing in Undiagnosed Axonal CMT Patients
The answer is hiding in your DNA. For some, it hasn’t been found yet. This CMTA-funded study uses long-read sequencing to uncover genetic causes of CMT that standard tests may miss.
Allele-Specific Silencing of MFN2 to Treat Peripheral Neuropathy
With CMTA support of $300,000, CMTA Strategy To Accelerate Research (CMTA-STAR) Advisory Board member Bruce...
CMTA’s $300K Investment in CRISPR for CMT2A
The Charcot-Marie-Tooth Association (CMTA) is investing $300,000 in a groundbreaking gene editing research project at...
